• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于模糊逻辑和 Lyapunov 的 HCV 感染非线性控制器。

Fuzzy logic and Lyapunov-based non-linear controllers for HCV infection.

机构信息

Department of Electrical Engineering, School of Electrical Engineering and Computer Science, National University of Sciences and Technology (NUST), Islamabad, Pakistan.

出版信息

IET Syst Biol. 2021 Apr;15(2):53-71. doi: 10.1049/syb2.12014.

DOI:10.1049/syb2.12014
PMID:33780147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8675797/
Abstract

Hepatitis C is the liver disease caused by the Hepatitis C virus (HCV) which can lead to serious health problems such as liver cancer. In this research work, the non-linear model of HCV having three state variables (uninfected hepatocytes, infected hepatocytes and virions) and two control inputs has been taken into account, and four non-linear controllers namely non-linear PID controller, Lyapunov Redesign controller, Synergetic controller and Fuzzy Logic-Based controller have been proposed to control HCV infection inside the human body. The controllers have been designed for the anti-viral therapy in order to control the amount of uninfected hepatocytes to the desired safe limit and to track the amount of infected hepatocytes and virions to their reference value which is zero. One control input is the Pegylated interferon (peg-IFN-α) which acts in reducing the infected hepatocytes and the other input is ribavirin which blocks the production of virions. By doing so, the uninfected hepatocytes increase and achieve the required safe limit. Lyapunov stability analysis has been used to prove the stability of the whole system. The comparative analysis of the proposed nonlinear controllers using MATLAB/Simulink have been done with each other and with linear PID. These results depict that the infected hepatocytes and virions are reduced to the desired level, enhancing the rate of sustained virologic response (SVR) and reducing the treatment period as compared with previous strategies introduced in the literature.

摘要

丙型肝炎是由丙型肝炎病毒(HCV)引起的肝脏疾病,可导致严重的健康问题,如肝癌。在这项研究工作中,考虑了具有三个状态变量(未感染的肝细胞、感染的肝细胞和病毒)和两个控制输入的 HCV 的非线性模型,并提出了四种非线性控制器,即非线性 PID 控制器、Lyapunov 重新设计控制器、协同控制器和基于模糊逻辑的控制器,以控制人体内的 HCV 感染。这些控制器是为抗病毒治疗而设计的,旨在将未感染的肝细胞数量控制在所需的安全限度内,并将感染的肝细胞和病毒数量跟踪到其参考值零。一个控制输入是聚乙二醇干扰素(peg-IFN-α),它可以减少感染的肝细胞,另一个输入是利巴韦林,它可以阻止病毒的产生。这样,未感染的肝细胞就会增加,并达到所需的安全限度。使用 Lyapunov 稳定性分析证明了整个系统的稳定性。使用 MATLAB/Simulink 对提出的非线性控制器进行了相互比较和与线性 PID 的比较分析。这些结果表明,与文献中介绍的以前的策略相比,感染的肝细胞和病毒数量减少到所需水平,提高了持续病毒学应答(SVR)的速度,并缩短了治疗期。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e02fb77bb3b8/SYB2-15-53-g025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/08a98f1d0a0e/SYB2-15-53-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6738a35d9061/SYB2-15-53-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/87e5f2ef54a0/SYB2-15-53-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/b29e38467dbe/SYB2-15-53-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/dddfea60305c/SYB2-15-53-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/23145031ff96/SYB2-15-53-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/1e55455dada3/SYB2-15-53-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e1636a7bc01b/SYB2-15-53-g028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/02e961fec3e4/SYB2-15-53-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/fc8a5e07f852/SYB2-15-53-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/a21c50e08cea/SYB2-15-53-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/99b5d51045ba/SYB2-15-53-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/2a7a5a623f0a/SYB2-15-53-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/0251b85f9d6b/SYB2-15-53-g029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/cd70bb051c67/SYB2-15-53-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/eb52a7270fb4/SYB2-15-53-g024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/5bfcb31ea691/SYB2-15-53-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/5fdf393a7fdd/SYB2-15-53-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6a83bdd57232/SYB2-15-53-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/b755d8104b0a/SYB2-15-53-g026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/0691785dcce6/SYB2-15-53-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e33b5e1cfe1f/SYB2-15-53-g027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/9e3973f48a03/SYB2-15-53-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/c4d425e653d5/SYB2-15-53-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/19ea4dc6e096/SYB2-15-53-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/08698c459638/SYB2-15-53-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/2353fc053310/SYB2-15-53-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6036af9d09b6/SYB2-15-53-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e02fb77bb3b8/SYB2-15-53-g025.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/08a98f1d0a0e/SYB2-15-53-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6738a35d9061/SYB2-15-53-g021.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/87e5f2ef54a0/SYB2-15-53-g023.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/b29e38467dbe/SYB2-15-53-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/dddfea60305c/SYB2-15-53-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/23145031ff96/SYB2-15-53-g018.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/1e55455dada3/SYB2-15-53-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e1636a7bc01b/SYB2-15-53-g028.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/02e961fec3e4/SYB2-15-53-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/fc8a5e07f852/SYB2-15-53-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/a21c50e08cea/SYB2-15-53-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/99b5d51045ba/SYB2-15-53-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/2a7a5a623f0a/SYB2-15-53-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/0251b85f9d6b/SYB2-15-53-g029.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/cd70bb051c67/SYB2-15-53-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/eb52a7270fb4/SYB2-15-53-g024.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/5bfcb31ea691/SYB2-15-53-g022.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/5fdf393a7fdd/SYB2-15-53-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6a83bdd57232/SYB2-15-53-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/b755d8104b0a/SYB2-15-53-g026.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/0691785dcce6/SYB2-15-53-g019.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e33b5e1cfe1f/SYB2-15-53-g027.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/9e3973f48a03/SYB2-15-53-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/c4d425e653d5/SYB2-15-53-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/19ea4dc6e096/SYB2-15-53-g017.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/08698c459638/SYB2-15-53-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/2353fc053310/SYB2-15-53-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/6036af9d09b6/SYB2-15-53-g020.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dd2/8675797/e02fb77bb3b8/SYB2-15-53-g025.jpg

相似文献

1
Fuzzy logic and Lyapunov-based non-linear controllers for HCV infection.基于模糊逻辑和 Lyapunov 的 HCV 感染非线性控制器。
IET Syst Biol. 2021 Apr;15(2):53-71. doi: 10.1049/syb2.12014.
2
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.在对聚乙二醇干扰素α-2a和利巴韦林有反应的丙型肝炎病毒2型和3型患者中提前停用利巴韦林。
J Viral Hepat. 2009 Jan;16(1):28-35. doi: 10.1111/j.1365-2893.2008.01044.x. Epub 2008 Aug 28.
3
Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.丙型肝炎病毒1b型且病毒载量高的患者的病毒学应答:聚乙二醇化干扰素-α-2a联合利巴韦林剂量减少及宿主相关因素的影响
Clin Drug Investig. 2008;28(1):9-16. doi: 10.2165/00044011-200828010-00002.
4
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.博赛泼维联合聚乙二醇干扰素/利巴韦林用于重新治疗HIV-HCV合并感染患者的丙型肝炎病毒1型:西班牙BOC HIV-HCV研究的最终结果
Int J Infect Dis. 2016 Dec;53:46-51. doi: 10.1016/j.ijid.2016.10.028. Epub 2016 Nov 1.
5
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection.近期丙型肝炎病毒治疗期间的病毒学应答:利巴韦林用于丙型肝炎/艾滋病病毒合并感染的潜在益处。
AIDS. 2012 Aug 24;26(13):1653-61. doi: 10.1097/QAD.0b013e3283553719.
6
Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.基于干扰素联合利巴韦林治疗的HIV/丙型肝炎病毒合并感染患者早期病毒学应答的预测价值
J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):174-8. doi: 10.1097/QAI.0b013e31802b812d.
7
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.聚乙二醇干扰素联合利巴韦林治疗代偿期肝硬化的 HIV/丙型肝炎病毒合并感染患者的应答。
Clin Infect Dis. 2012 Dec;55(12):1719-26. doi: 10.1093/cid/cis779. Epub 2012 Sep 5.
8
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.利用 HCV 基因型、IL28B 变异和 HCV-RNA 载量预测 HIV/丙型肝炎病毒 (HCV) 合并感染患者对聚乙二醇干扰素加利巴韦林的反应。
J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.
9
Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.荟萃分析:IL28B 多态性可预测聚乙二醇干扰素-α和利巴韦林治疗的 HCV 患者的持续病毒应答。
Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.
10
NIH Consensus Statement on Management of Hepatitis C: 2002.美国国立卫生研究院关于丙型肝炎管理的共识声明:2002年。
NIH Consens State Sci Statements. 2002;19(3):1-46.

本文引用的文献

1
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.使用直接作用抗病毒药物进行超短疗程治疗后的丙型肝炎病毒治愈模型
Antiviral Res. 2017 Aug;144:281-285. doi: 10.1016/j.antiviral.2017.06.019. Epub 2017 Jun 30.
2
Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.丙型肝炎病毒感染的全球流行病学:丙型肝炎病毒基因型分布与传播的最新情况
World J Gastroenterol. 2016 Sep 14;22(34):7824-40. doi: 10.3748/wjg.v22.i34.7824.
3
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
丙型肝炎病毒动力学和模型分析表明,在索非布韦与达卡他韦、西米普韦或来迪帕司韦的联合治疗方案中,达到治愈的时间相似。
J Hepatol. 2016 Jun;64(6):1232-9. doi: 10.1016/j.jhep.2016.02.022. Epub 2016 Feb 22.
4
Role of Interferons in Chronic Hepatitis C Infection.干扰素在慢性丙型肝炎感染中的作用。
Curr Drug Targets. 2017;18(7):844-850. doi: 10.2174/1389450117666160201112632.
5
Dynamical analysis on a chronic hepatitis C virus infection model with immune response.具有免疫反应的慢性丙型肝炎病毒感染模型的动力学分析
J Theor Biol. 2015 Jan 21;365:337-46. doi: 10.1016/j.jtbi.2014.10.039. Epub 2014 Nov 7.
6
Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.两种核苷酸类似物(索磷布韦(GS-7977)和GS-0938)给药期间丙型肝炎病毒动力学分析
Antivir Ther. 2014;19(2):211-20. doi: 10.3851/IMP2733. Epub 2014 Jan 24.
7
Ultrastructural analysis of hepatitis C virus particles.丙型肝炎病毒颗粒的超微结构分析。
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9505-10. doi: 10.1073/pnas.1307527110. Epub 2013 May 20.
8
Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?利巴韦林在抗丙型肝炎病毒治疗方案中的作用机制:一个古老问题的新见解?
Gut. 2014 Jan;63(1):3-4. doi: 10.1136/gutjnl-2013-304528. Epub 2013 May 9.
9
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.模型显示,NS5A 抑制剂达卡他韦有两种作用模式,从而缩短了丙型肝炎病毒半衰期的估计值。
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110. Epub 2013 Feb 19.
10
Viral dynamics model with CTL immune response incorporating antiretroviral therapy.纳入抗逆转录病毒疗法且具有细胞毒性T淋巴细胞免疫反应的病毒动力学模型。
J Math Biol. 2013 Oct;67(4):901-34. doi: 10.1007/s00285-012-0580-3. Epub 2012 Aug 29.